101 
0 Kommentare
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
- Destiny Pharma to present XF-73 at ESCMID 2024.
- XF-73 shows >99% reduction in S. aureus nasal burden.
- Fewer patients needed post-op antibiotics with XF-73.
|
JP Jenkins Ltd 20th Aug 2024 |
JPJ: DEST
ISIN: GB00BDHSP575
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascular Surgery Patients.
Brighton, United Kingdom – 20 August 2024 – Destiny Pharma, a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, today announced that clinical data from its Phase 2b clinical trial on XF-73 nasal administered to cardiac surgery patients has been accepted for an oral presentation at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) conference, the leading European conference on infectious disease in Porto, Portugal, entitled ‘meeting the challenge of antimicrobial resistance’, 17-20 September 2024.
S. aureus bacterial nasal carriage, (including MRSA), has been established as an important risk factor for the development of bacteremia and surgical site infections (SSIs) in cardio-thoracic surgery. The decolonidation of S. aureus nasal carriage prior to cardiac high-risk surgery forms part of current global guidelines for surgical infection prevention. Mupirocin is widely used as a nasal antibiotic for the treatment of nasal carriage of S. aureus but has significant limitations including a lengthy five day dosing and the widespread emergence of Mupirocin-resistant bacterial strains.
URL kopieren
Per E-Mail teilen
Artikel drucken